Bijan Etemad-Gilbertson, PhD, Head of Antibody Technology, NextPoint TherapeuticsBijan Etemad-Gilbertson, PhDBijan Etemad-Gilbertson has over twenty-two years of industry experience working on antibody therapeutics for cancer at both large and small biotech companies. We are also creating an anti-drug activity assay to spot whether the patients immune system makes antibodies versus our particle, which would be harmful to the success of our drug because the immune system would clear the antibody and prevent it from working.How are you partnering with Fortis to advance this work?We contract out a lot of our work through CROs– there are just twelve of us in the business and even though were just three years old, we currently have a substantial pipeline. They vaccinate bunnies with our molecule, gather the B cells– which produce a really particular bunny antibody– and screen that antibody to make sure it acknowledges our particle.
Bijan Etemad-Gilbertson, PhD, Head of Antibody Technology, NextPoint TherapeuticsBijan Etemad-Gilbertson, PhDBijan Etemad-Gilbertson has over twenty-two years of market experience working on antibody therapeutics for cancer at both small and large biotech companies. We are likewise generating an anti-drug activity assay to spot whether the clients immune system makes antibodies versus our molecule, which would be detrimental to the success of our drug due to the fact that the immune system would clear the antibody and prevent it from working.How are you partnering with Fortis to advance this work?We contract out a lot of our work through CROs– there are only twelve of us in the business and even though were just 3 years old, we already have a huge pipeline. We sent them our antibody of interest and an isotype control, which is an antibody that is precisely the very same as ours except in the binding website. They vaccinate bunnies with our particle, collect the B cells– which produce a really particular rabbit antibody– and screen that antibody to make sure it acknowledges our molecule.